Augelli-Szafran brings more than 25 years of practical and managerial experience in medicinal chemistry and drug discovery gained from leading research programs at institutions and pharmaceutical companies. Prior to joining Southern Research, Augelli-Szafran was director of the Laboratory for Experimental Alzheimer’s Drugs at Harvard Medical School and Brigham and Women’s Hospital in Boston. In that position, she built a fully functional medicinal chemistry and drug discovery laboratory focused on the development of gamma-secretase Notch-sparing inhibitors for the therapeutic indication of Alzheimer’s disease. Prior to Harvard, Augelli-Szafran held a number of leadership roles at Parke-Davis Pharmaceutical Research and Pfizer Global Research and Development. As co-chair and project leader, she investigated central nervous system therapeutics with an emphasis in neurodegeneration, mainly in Alzheimer’s disease therapeutics, but also in the areas of cardiovascular, atherosclerosis, psychotherapeutics, and inflammation and pain.
May 16, 2022 | Southern Research
January 18, 2022 | Southern Research
March 25, 2021 | Southern Research